Abstract: The present invention relates to a companion diagnosis biomarker composition and a companion diagnosis kit containing the same and, particularly, to a companion diagnosis biomarker composition for predicting a therapeutic response to at least one immune checkpoint inhibitor from among a PD-1 immune checkpoint inhibitor and a PD-L1 immune checkpoint inhibitor, and a companion diagnosis kit containing the same. According to the present invention, there is an effect that it is possible to predict a therapeutic response to at least one immune checkpoint inhibitor from among a PD-1 immune checkpoint inhibitor and a PD-L1 immune checkpoint inhibitor not only through a companion diagnosis through cancer patient tissues, but also through proteomic analysis of cancer patient blood.

Abstract: The present invention relates to an apparatus for diagnosing solid cancers comprising lung cancer, pancreatic cancer, bile duct cancer, colorectal cancer, breast cancer, gastric cancer, brain tumors, kidney cancer, liver cancer, and cervical cancer. More specifically, the apparatus comprises: a concentration measurement unit for measuring the concentration of each of acyl-carnitine (AC), nudifloramide (2PY), and lysophosphatidylcholine (LPC) from a biological sample; a pre-processing unit for pre-processing the measured concentrations; and a diagnosis unit for determining the diagnosis information of cancer through linear discriminant analysis using the pre-processed concentrations.

Abstract: The present disclosure relates to a method for providing diagnostic information for biliary tract cancer and an apparatus for diagnosing biliary tract cancer. According to an aspect of the present disclosure, there is provided a method for providing diagnostic information for biliary tract cancer including obtaining biological samples; measuring concentration of a marker for predicting biliary tract cancer in the biological samples; and providing diagnostic information for biliary tract cancer using the measured concentration of the marker, where the marker includes Nudifloramide.

Abstract: The present invention relates to a device of diagnosing a colorectal cancer and a method for providing colorectal cancer diagnosis information. A colorectal cancer diagnosing device according to the present invention includes: an input unit which acquires mass spectrometry data measured from a biological sample; a concentration detecting unit which measures a concentration of nudifloramide from the acquired mass spectrometry data; and a diagnosing unit which determines diagnosis information of the colorectal cancer based on a measurement result of the concentration detecting unit.

Abstract: The present invention relates to a natural fermented composition of pollen using glacial snow water obtained by mixing pollen, such as bee pollen, pollen, and edible flowers, with glacial snow water and fermenting same, and a preparation method therefor. In the present invention, provided is a composition obtained by mixing glacial snow water having a pH of 7.5 to 8.8 and a density of 0.05-0.85 g/cm3 with one or more kinds of pollens selected from bee pollen, pollen, flower buds, floral leaves, and floral nectaries and fermenting the mixture for three months or longer without inoculation of microorganisms. The natural fermented composition of the pollens of the present invention contains a wide variety of nutritional and active ingredients, and can exhibit various effects. Especially, since the composition has excellent antioxidative effects, the composition may be used for foods and beverages, antioxidant drinks, etc.

Abstract: The present invention relates to a device of diagnosing a colorectal cancer and a method for providing colorectal cancer diagnosis information. A colorectal cancer diagnosing device according to the present invention includes: an input unit which acquires mass spectrometry data measured from a biological sample; a concentration detecting unit which measures a concentration of nudifloramide from the acquired mass spectrometry data; and a diagnosing unit which determines diagnosis information of the colorectal cancer based on a measurement result of the concentration detecting unit.

Abstract: The present disclosure relates to a method for providing diagnostic information for biliary tract cancer and an apparatus for diagnosing biliary tract cancer. According to an aspect of the present disclosure, there is provided a method for providing diagnostic information for biliary tract cancer including obtaining biological samples; measuring concentration of a marker for predicting biliary tract cancer in the biological samples; and providing diagnostic information for biliary tract cancer using the measured concentration of the marker, where the marker includes Nudifloramide.

Abstract: The present invention provides an apparatus for screening cancer, which reads low-mass ion mass spectrum for diagnosing cancer based on biostatistical analysis with respect to low-mass ions extracted from biological materials, and diagnoses cancer using the low-mass ion spectrum. An apparatus for cancer diagnosis, including a low-mass ion detecting unit which detects mass spectra of low-mass ions of biological materials; a cancer diagnosing unit which compares and analyzes patterns of mass spectra and diagnoses cancer; a display unit which displays cancer diagnosis information from the cancer diagnosing unit.

Abstract: Provided are methods of treating a subject for of ovarian cancer, the method including using lysophosphatidylcholine (16:0) and homocysteic acid, which are low-mass ions present in biological samples, to diagnose whether treatment should be provided. The method enables ovarian cancer to be diagnosed in a cost-effective, rapid and accurate manner.

Abstract: The present invention provides a method for determining low mass ions for diagnosing colorectal cancer by using a MALDI-TOF mass spectrometer to biostatistically analyze low mass ions, which are extracted from a biological sample, and a method for providing information for diagnosing colorectal cancer using same. The present inventions can provide a diagnostic method, which requires low cost and a short time for analysis, can analyze large areas, and which can provide superior and credible discriminations.

Abstract: The present invention relates to diagnosis of ovarian cancer using lysophosphatidylcholine (16:0) and homocysteic acid, which are low-mass ions present in biological samples. The use of the present invention enables ovarian cancer to be diagnosed in a cost-effective, rapid and accurate manner. Thus, it is expected that the present invention will be effectively used to diagnose and treat ovarian cancer.

Abstract: The present invention relates to a disease diagnosis method, a marker screening method, and a marker using a time-of-flight secondary ion mass spectrometry (TOF-SIMS), and more particularly, to a large intestine cancer diagnosis method, a large intestine cancer marker screening method, and a large intestine cancer marker using a time-of-flight secondary ion mass spectrometry (TOF-SIMS). Specifically, the present invention provides a method diagnosing a disease using a pattern of secondary ion mass (m/z) peaks of biological samples measured using a time-of-flight secondary ion mass spectrometry (TOF-SIMS) as a marker, a marker screening method being a reference judging an existence or non-existence of a disease, and a marker configured of specific secondary ion mass peaks.

Abstract: The present invention provides an apparatus for screening cancer, which reads low-mass ion mass spectrum for diagnosing cancer based on biostatistical analysis with respect to low-mass ions extracted from biological materials, and diagnoses cancer using the low-mass ion spectrum. An apparatus for cancer diagnosis, including a low-mass ion detecting unit which detects mass spectra of low-mass ions of biological materials; a cancer diagnosing unit which compares and analyzes patterns of mass spectra and diagnoses cancer; a display unit which displays cancer diagnosis information from the cancer diagnosing unit.

Abstract: The present invention provides a method for crystallizing low mass ions for diagnosing colorectal cancer by using a MALDI-TOF mass spectrometer to biostatistically analyze low mass ions, which are extracted from a biological sample, and a method for providing information for diagnosing colorectal cancer using same. The present inventions can provide a diagnostic method, which requires low cost and a short time for analysis, can analyze large areas, and which can provide superior and credible discriminations.

Abstract: The present invention relates to a disease diagnosis method, a marker screening method, and a marker using a time-of-flight secondary ion mass spectrometry (TOF-SIMS), and more particularly, to a large intestine cancer diagnosis method, a large intestine cancer marker screening method, and a large intestine cancer marker using a time-of-flight secondary ion mass spectrometry (TOF-SIMS). Specifically, the present invention provides a method diagnosing a disease using a pattern of secondary ion mass (m/z) peaks of biological samples measured using a time-of-flight secondary ion mass spectrometry (TOF-SIMS) as a marker, a marker screening method being a reference judging an existence or non-existence of a disease, and a marker configured of specific secondary ion mass peaks.

Abstract: The present invention relates to a disease diagnosis method, a marker screening method, and a marker using a time-of-flight secondary ion mass spectrometry (TOF-SIMS), and more particularly, to a large intestine cancer diagnosis method, a large intestine cancer marker screening method, and a large intestine cancer marker using a time-of-flight secondary ion mass spectrometry (TOF-SIMS). Specifically, the present invention provides a method diagnosing a disease using a pattern of secondary ion mass (m/z) peaks of biological samples measured using a time-of- flight secondary ion mass spectrometry (TOF-SIMS) as a marker, a marker screening method being a reference judging an existence or non-existence of a disease, and a marker configured of specific secondary ion mass peaks.

Abstract: The present invention relates to a disease diagnosis method, a marker screening method, and a marker using a time-of-flight secondary ion mass spectrometry (TOF-SIMS), and more particularly, to a large intestine cancer diagnosis method, a large intestine cancer marker screening method, and a large intestine cancer marker using a time-of-flight secondary ion mass spectrometry (TOF-SIMS). Specifically, the present invention provides a method diagnosing a disease using a pattern of secondary ion mass (m/s) peaks of biological samples measured using a time-of- flight secondary ion mass spectrometry (TOF-SIMS) as a marker, a marker screening method being a reference judging an existence or non-existence of a disease, and a marker configured of specific secondary ion mass peaks.

Abstract: A kit and a composition comprising Herceptin, an antibody binding specifically to HER2, based on detecting Herceptin-sensitive HER2-overexpressing cells are provided for diagnosing cancer. A method of detecting Herceptin-sensitive HER2-overexpressing cells using the same is also provided.